AstraZeneca ADR saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 94 the day before.
The new score indicates the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
AstraZeneca ADR is not currently near a proper buy point. See if the stock goes on to form a new chart pattern and offer a new buying opportunity.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The stock has a 97 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 97% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 44% rise in earnings for Q4. That means it's now posted two straight quarters of rising EPS gains. Sales growth increased 24%, up from 18% in the prior report. The company has now posted increasing growth in each of the last two reports.
AstraZeneca ADR holds the No. 1 rank among its peers in the Medical-Diversified industry group. Eli Lilly and Abbott Laboratories are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
